ゴーシェ病治療の世界市場2026

Effectual Servicesが発行した調査報告書(DATA90511)
◆英語タイトル:Gaucher Disease Market Report - 2026
◆商品コード:DATA90511
◆発行会社(リサーチ会社):Effectual Services
◆発行日:2018年8月
◆ページ数:145
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single UserUSD3,499 ⇒換算¥377,892見積依頼/購入/質問フォーム
Global Site LicenseUSD5,499 ⇒換算¥593,892見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はEffectual Services社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Effectual Services社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Gaucher Disease is a rare multi-systemic metabolic disorder which occurs due to the defective or insufficient activity of the glucocerebrosidase enzyme. The disease leads to the accumulation of substrate, glucocerebroside in tissue macrophages, and damage to hematological, visceral, and bone systems. Painless splenomegaly, anemia, thrombocytopenia, chronic fatigue, hepatomegaly, bone pain, pathologic fractures, and others are the most frequent manifestations of Gaucher Disease.Gaucher Disease is classified as Gaucher Disease Type 1, Gaucher Disease Type 2 and Gaucher Disease Type 3 based on clinical subtypes. The United States accounts for the highest prevalence of the disease with 8,000 cases, followed by EU5 (the United Kingdom, Germany, France, and Italy) and Japan. Gaucher Disease Type 1 is more prevalent in comparison to Gaucher Disease Type 2 and Gaucher Disease Type 3.
The market size of Gaucher Disease in seven major markets is expected to reach $1,456 million in 2026. The United States accounts for the highest market share in comparison to EU5 (United Kingdom, Germany, France, and Italy) and Japan, as the US has the highest prevalence of cases, increasing research activities, and improved healthcare resources. Among European countries, Germany accounts for the highest market share, followed by France.
Elelyso (taliglucerase alfa), Vpriv (velaglucerase alfa) and Cerezyme (imiglucerase) are the approved Enzyme Replacement Therapies, whereas miglustat (Zavesca) and eliglustat (Cerdelga) are the approved Substrate Reduction Therapies for the treatment of Gaucher Disease Type 1. The use of Enzyme Replacement Therapies has resulted in improved anemia and low platelet counts in patients, as well as reduced enlargement of the liver and spleen. Substrate Reduction Therapy provides a consistent dosage to patients in comparison to enzyme replacement therapy.
Major players such as Belrose Pharma, Sanofi-Genzyme, AVROBIO, Inc, Lixte Biotechnology Holdings, Inc., Orphazyme A.S and other companies are involved in developing therapies for the treatment of Gaucher Disease. The launch of emerging therapies such as Arimoclomol (2024) and Venglustat (2026) is expected to fuel market growth. An increase in the number of collaborations and agreements between companies and universities, improved diagnosis, and increasing awareness regarding Gaucher Disease will have a positive impact on the market during the forecasted period.

【レポートの目次】

1
Executive Summary
2
Gaucher Disease: Overview
Signs and Symptoms
Advancement in Gaucher Disease
Classification
Variants of Gaucher Disease
Etiology
Pathophysiology
Inheritance Pattern
Complications
Diagnosis
Diagnostic Algorithm
Gaucher Disease patients with Ashkenazi Origin
Gaucher Disease patients with Non- Ashkenazi Origin
3
Treatment
Treatment Algorithm
Treatment Guidelines
Screening and Management Guidelines of Hematological Malignancy
Criteria for using Enzyme Replacement Therapy
Treatment Recommendation for Adults with Gaucher Disease Type 1
4
Epidemiology
United States
Prevalent Cases of Gaucher Disease
Sub-type Specific Prevalent Cases of Gaucher Disease
Diagnosed Cases of Gaucher Disease
Age-Specific Diagnosed Cases for Gaucher Disease
Germany
Prevalent Cases of Gaucher Disease
Sub-type Specific Prevalent Cases of Gaucher Disease
Diagnosed Cases of Gaucher Disease
Age-Specific Diagnosed Cases for Gaucher Disease
France
Prevalent Cases of Gaucher Disease
Sub-type Specific Prevalent Cases of Gaucher Disease
Diagnosed Cases of Gaucher Disease
Age-Specific Diagnosed Cases for Gaucher Disease
United Kingdom
Prevalent Cases of Gaucher Disease
Sub-type Specific Prevalent Cases of Gaucher Disease
Diagnosed Cases of Gaucher Disease
Gaucher Disease Market Report 2018
©EffeMarket
Page 3
Age-Specific Diagnosed Cases for Gaucher Disease
Spain
Prevalent Cases of Gaucher Disease
Sub-type Specific Prevalent Cases of Gaucher Disease
Diagnosed Cases of Gaucher Disease
Age-Specific Diagnosed Cases for Gaucher Disease
Italy
Prevalent Cases of Gaucher Disease
Sub-type Specific Prevalent Cases of Gaucher Disease
Diagnosed Cases of Gaucher Disease
Age-Specific Diagnosed Cases for Gaucher Disease
Japan
Prevalent Cases of Gaucher Disease
Sub-type Specific Prevalent Cases of Gaucher Disease
Diagnosed Cases of Gaucher Disease
Age-Specific Diagnosed Cases for Gaucher Disease
5
Market Size of Gaucher Disease
United States
Market Size of Gaucher Disease
Therapy wise market Size of Gaucher Disease
EU5
Germany
France
United Kingdom
Spain
Italy
Japan
Market Size of Gaucher Disease
Therapy wise market Size of Gaucher Disease
6
Therapeutic Approaches for Gaucher Disease
7
Competitive Landscape
8
Marketed Drug Profiles
Cerdelga (eliglustat)
Drug Description
Development Activities
Pharmacokinetics
Pharmacodynamics
Adverse Events
Cerdelga Sales
Cerezyme (imiglucerase)
Drug Description
Development Activities
Gaucher Disease Market Report 2018
©EffeMarket
Page 4
Pharmacokinetics
Pharmacodynamics
Adverse Events
Cerezyme Sales
Vpriv (velaglucerase alfa)
Drug Description
Development Activities
Pharmacokinetics
Adverse Events
Vpriv Sales
Zavesca (Miglustat)
Drug Description
Development Activities
Pharmacokinetics
Adverse Events
Zavesca Sales
Elelyso (taliglucerase alfa)
Drug Description
Development Activities
Pharmacokinetics
Adverse Events
Elelyso Sales
9
Marketed Drug Analysis
Marketed Drug Analysis by Molecule Type
Marketed Drug Analysis by Route of Administration
10
Pipeline Product Analysis
Pipeline Analysis by Stage of Development
Pipeline Analysis by Route of Administration
Pipeline Analysis by Therapeutic Class
Pipeline Analysis by Targets
Pipeline Analysis by Molecule Type
11
Patent Landscape
Gaucher Disease Patent Trend by Focus Area
Gaucher Disease Patent Trend by Composition
Gaucher Disease Patent Trends by Enzyme Replacement Therapy
Gaucher Disease Patent Trends by Substrate Reduction Therapy
Gaucher Disease Composition patent trends by Supportive Therapies
Gaucher Disease Patent Trends by Route of Administration
Key Patents of Gaucher Disease
Gaucher Disease Patent trends by Key Players
Key players in patent focus
Key Players in Composition
Gaucher Disease Market Report 2018
©EffeMarket
Page 5
Collaborations of the Assignees
Gaucher Disease Patents Trends by Key Inventors
12
Market Dynamics
Growth Drivers
Technological advancement
Emerging Therapies
Increasing Research Activities
Challenges
Diagnostic Barriers
Socioeconomic Barriers
13
Companies Profiles
Pfizer
Business Overview
Financial Overview
Sanofi
Business Overview
Financial Overview
Shire Pharmaceuticals
Business Overview
Financial Overview
Johnson & Johnson
Business Overview
Financial Overview
14
About EffeMarket
15
Disclaimer
16
Contact US

Figure 1: Signs and Symptoms of Gaucher Disease
Figure 2: Advancement in Gaucher Disease (1/2)
Figure 3: Advancement in Gaucher Disease (2/2)
Figure 4: Classification of Gaucher Disease
Figure 5: Pathophysiology of Gaucher Disease
Figure 6: Inheritance Pattern of Gaucher Disease
Figure 7: Complications of Gaucher Disease
Figure 8: Diagnostic Algorithm for Gaucher Disease patients with Ashkenazi Origin
Figure 9: Diagnostic Algorithm for Gaucher Disease patients with the Non-Ashkenazi origin
Figure 10: Treatment Algorithm for Gaucher Disease
Figure 11: Prevalent cases of Gaucher Disease in 7 Major Markets (2016-2026)
Figure 12: Prevalent Cases of Gaucher Disease in the United States (2016-2026)
Figure 13: Sub-type Specific Prevalent Cases of Gaucher Disease in the United States (2016-2026)
Figure 14: Diagnosed Cases of Gaucher Disease in the United States (2016-2026)
Figure 15: Age-Specific Diagnosed Cases for Gaucher Disease in the United States (2016-2026)
Figure 16: Prevalent Cases of Gaucher Disease in Germany (2016-2026)
Figure 17: Sub-type Specific Prevalent Cases of Gaucher Disease in Germany (2016-2026)
Figure 18: Diagnosed Cases of Gaucher Disease in Germany (2016-2026)
Figure 19: Age-Specific Diagnosed Cases for Gaucher Disease in Germany (2017 &2026)
Figure 20: Prevalent Cases of Gaucher Disease in France (2016-2026)
Figure 21: Sub-type Specific Prevalent Cases of Gaucher Disease in France (2016-2026)
Figure 22: Diagnosed Cases of Gaucher Disease in France (2016-2026)
Figure 23: Age-Specific Diagnosed Cases for Gaucher Disease in France (2017 &2026)
Figure 24: Prevalent Cases of Gaucher Disease in the United Kingdom (2016-2026)
Figure 25: Sub-type Specific Prevalent Cases of Gaucher Disease in the United Kingdom (2016-2026)
Figure 26: Diagnosed Cases of Gaucher Disease in the United Kingdom (2016-2026)
Figure 27: Age-Specific Diagnosed Cases for Gaucher Disease in the United Kingdom (2017 &2026)
Figure 28: Prevalent Cases of Gaucher Disease in Spain (2016-2026)
Figure 29: Sub-type Specific Prevalent Cases of Gaucher Disease in Spain (2016-2026)
Figure 30: Diagnosed Cases of Gaucher Disease in Spain (2016-2026)
Figure 31: Age-Specific Diagnosed Cases for Gaucher Disease in Spain (2017 &2026)
Figure 32: Prevalent Cases of Gaucher Disease in Italy (2016-2026)
Figure 33: Sub-type Specific Prevalent Cases of Gaucher Disease in Italy (2016-2026)
Figure 34: Diagnosed Cases of Gaucher Disease in Italy (2016-2026)
Figure 35: Age-Specific Diagnosed Cases for Gaucher Disease in Italy (2017 &2026)
Figure 36: Prevalent Cases of Gaucher Disease in Japan (2016-2026)
Figure 37: Sub-type Specific Prevalent Cases of Gaucher Disease in Japan (2016-2026)
Figure 38: Diagnosed Cases of Gaucher Disease in Japan (2016-2026)
Figure 39: Age-Specific Diagnosed Cases for Gaucher Disease in Japan (2017 &2026)
Figure 40: 7 Major Market Size of Gaucher Disease, In USD Million (2016-2026)
Figure 41: Market Size of Gaucher Disease in the United States, in USD Million (2016-2026)
Figure 42: Therapy Wise Market Size of Gaucher Disease in the United States, in USD Million (2016-2026)
Figure 43: EU5 Market Size of Gaucher Disease, in USD Million (2016-2026)
Figure 44: Market Size of Gaucher Disease in Germany, in USD Million (2016-2026)
Figure 45: Therapy Wise Market Size of Gaucher Disease in Germany, in USD Million (2016-2026)
Figure 46: Market Size of Gaucher Disease in France, in USD Million (2016-2026)
Figure 47: Therapy Wise Market Size of Gaucher Disease in France, in USD Million (2016-2026)
Figure 48: Market Size of Gaucher Disease in the United Kingdom, in USD Million (2016-2026)
Figure 49: Therapy Wise Market Size of Gaucher Disease in the United Kingdom, in USD Million (2016-2026)
Figure 50: Market Size of Gaucher Disease in Spain, in USD Million (2016-2026)
Figure 51: Therapy Wise Market Size of Gaucher Disease in Spain, in USD Million (2016-2026)
Figure 52: Market Size of Gaucher Disease in Italy, in USD Million (2016-2026)
Figure 53: Therapy Wise Market Size of Gaucher Disease in Italy, in USD Million (2016-2026)
Figure 54: Market Size of Gaucher Disease in Japan, in USD Million (2016-2026)
Figure 55: Therapy Wise Market Size of Gaucher Disease in Japan, in USD Million (2016-2026)
Figure 56: Therapeutic Approaches for Gaucher Disease
Figure 57: Mechanism of Action of Substrate Reduction Therapy and Enzyme Replacement Therapy
Figure 58: Cerdelga Sales In USD Million, (2014-2017)
Figure 59: Cerezyme Sales in USD Million (2014-2017)
Figure 60: Vpriv Sales in USD Million (2014-2017)
Figure 61: Zavesca Sales in USD Million (2014-2017)
Figure 62 Elelyso Sales in USD Million (2014-2017)
Figure 63: Marketed Drug Analysis by Molecule Type
Figure 64: Marketed Drug Analysis by Molecule Type
Figure 65: Pipeline Analysis by Stage of Development
Figure 66: Pipeline Analysis by Route of Administration
Figure 67: Pipeline Analysis by Therapeutic Class
Figure 68: Pipeline Analysis by Targets
Figure 69: Pipeline Analysis by Molecule Type
Figure 70: Overall IP Trends of Gaucher Disease; 1975-2018
Figure 71: Earliest Priority Country Filing Trend of Gaucher Disease; 1975-2018
Figure 72: Gene Therapy Patent Trend by Focus Area; 1975-2018
Figure 73: Gaucher Disease Composition patent trends by Enzyme Replacement Therapy; 1975-2018
Figure 74: Gaucher Disease Composition patent trends by Substrate Reduction Therapy; 1975-2018
Figure 75: Gaucher Disease Composition patent trends by Substrate Reduction Therapy; 1975-2018
Figure 76: Gaucher Disease Patent Trends by Route of Administration; 1975-2018
Figure 77: Gaucher Disease Patent trends by Key Players; 1975-2018
Figure 78: Gaucher Disease Patent trends by Key Inventors
Figure 79: Total Revenues of Pfizer in USD Billion (2014-2017)
Figure 80: Segmentation of Pfizer’s Revenues (2017)
Figure 81: Total Revenues of Sanofi in USD Billion (2014-2017)
Figure 82: Segmentation of Sanofi’s Revenues (2017)
Figure 83: Total Revenues of Shire Pharmaceuticals in USD Billion (2014-2017)
Figure 84: Segmentation of Shire’s Revenues (2017)
Figure 85: Total Revenue of Johnson & Johnson in USD Billion (2014-2017)
Figure 86 : Segmentation of Johnson & Johnson ‘s Revenues (2017)


【掲載企業】

Belrose Pharma, Sanofi-Genzyme, AVROBIO, Inc, Lixte Biotechnology Holdings, Inc., Orphazyme A.S

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ゴーシェ病治療の世界市場2026(Gaucher Disease Market Report - 2026)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆